Mode
Text Size
Log in / Sign up

WBRT yields median survival of 3.6 months in Nigerian brain metastases patientsBrain radiation extends life by 3.6 months in Nigerian patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret WBRT in Nigerian brain metastases patients as providing modest survival benefit (median 3.6 months) with 53.8% complete response.

This systematic review examined outcomes of whole brain radiotherapy (WBRT) in 142 patients with brain metastases in Nigeria. The primary outcome was survival period; secondary outcomes included complete clinical response, WHO performance status, and toxicities.

The median survival period was 3.6 months (95% CI 2.8-4.4). Complete clinical response was observed in 53.8% of patients. Most patients were female (90.1%), with a mean age of 47.3 ± 12.4 years. Breast cancer was the source of metastases in 82.4% of cases, and 66.7% had primary tumor stage 3. Multiple metastatic lesions were present in 85.9%, and 76.9% had supratentorial lesions.

Limitations acknowledged by the authors include modest survival outcomes and gaps in outcome reporting. The review is based on existing literature, and results depend on the quality of included studies. No comparator was reported, and follow-up duration was not specified.

WBRT provides symptomatic benefit but is limited by modest survival outcomes. The findings highlight the need for improved access to advanced treatment techniques in resource-limited settings.

How this fits prior evidence

This systematic review extends prior coverage of breast cancer treatments by focusing on brain metastases in a Nigerian cohort. While prior items highlighted improved PFS with tucatinib and noninferior pCR with THP in HER2+ disease, this review underscores the modest survival (median 3.6 months) and high complete response rate (53.8%) with WBRT in a setting with limited access to advanced therapies. It contrasts with the more favorable outcomes seen in trials with targeted agents, reflecting real-world challenges in resource-limited populations.

For people in Nigeria whose breast cancer has spread to the brain, a common treatment called whole brain radiotherapy (WBRT) offers a modest survival benefit. A new systematic review of 142 patients found that after WBRT, the median survival was just 3.6 months. That means half of patients lived longer than that, half less.

The review, which looked at existing studies from Nigeria, also found that about 54% of patients had a complete clinical response. Most patients were women (90%), with an average age of 47. The vast majority (82%) had breast cancer as the source of their brain metastases, and many had advanced disease.

It's important to note that this is a review of existing research, not a new clinical trial. The quality of the included studies may vary, and the survival outcomes are modest. The authors point out that WBRT is the most common treatment in Nigeria because access to advanced techniques is limited. While the treatment can help with symptoms, it does not offer a cure.

This information can help patients and doctors have realistic conversations about what to expect from WBRT. If you or a loved one is facing this decision, talk to your healthcare provider about the benefits and limitations based on your specific situation.

What this means for you:
Whole brain radiotherapy offers a modest survival benefit of about 3.6 months for Nigerian patients with brain metastases from breast cancer.

Common questions

What is whole brain radiotherapy (WBRT)?

Whole brain radiotherapy is a type of radiation treatment that targets the entire brain. It is often used to treat cancer that has spread to the brain from another part of the body, such as the breast. The goal is to shrink tumors and relieve symptoms, but it is not a cure.

How long do patients live after whole brain radiotherapy?

In this review of 142 Nigerian patients, the median survival after WBRT was 3.6 months. That means half of the patients lived longer than 3.6 months, and half lived less. Survival can vary based on individual factors like overall health and how far the cancer has spread.

What are the side effects of whole brain radiotherapy?

This review did not report on side effects or toxicities. In general, WBRT can cause short-term side effects like fatigue, hair loss, and skin irritation. Long-term effects may include memory problems or cognitive changes. Talk to your doctor about what to expect.

Is whole brain radiotherapy the only option for brain metastases in Nigeria?

According to this review, WBRT is the most commonly used treatment in Nigeria because access to advanced techniques like stereotactic radiosurgery is limited. Your doctor can discuss the best options based on your specific situation and available resources.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Whole brain radiotherapy (WBRT) remains the most commonly used treatment for brain metastases in Nigeria due to limited access to advanced radiotherapy techniques. However, evidence on its outcomes within the Nigerian context has not been systematically summarized. A PRISMA-guided systematic review was conducted to identify studies reporting the use of WBRT for brain metastases in Nigeria by systematic searching of PubMed/Medline, Google Scholar, Embase, and Ajol. Data were extracted on study characteristics, primary tumor profiles, treatment protocols, clinical outcomes, Karnofsky and WHO performance status, and toxicities. studies were included in this review, involving a total of 142 patients, with 128 females accounting for 90.1% of the sample size. The mean age was 47.3 ± 12.4 years. CT scan accounts for 70.6% of investigation modalities, MRI (23.5%), Both (5.9%). Mean KPS is 50, breast Cancer accounts for 82.4% of the source of metastases, 66.7% of primary tumors are in stage 3. Multiple metastatic lesions are seen in 85.9% of cases, while 76.9% of cases are supratentorial. Steroid (35%), surgery (9%), and chemotherapy (3%) are additional therapies received. Median survival period ranges between 3 to 18 months with a pooled median survival period of 3.6 months (95% CI: 2.8, 4.4), complete clinical response is seen in 53.8% of patients, with whole brain radiotherapy and improvements in WHO performance status following therapy. WBRT continues to provide symptomatic benefit for patients with brain metastases in Nigeria, but is limited by modest survival outcomes and gaps in outcome reporting. Improved access to advanced radiotherapy techniques and standardized reporting are needed to optimize care.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.